One-Year Trajectory of Cognitive Changes in Older Survivors of COVID-19 in Wuhan, China: A Longitudinal Cohort Study
Overview
Authors
Affiliations
Importance: Determining the long-term impact of COVID-19 on cognition is important to inform immediate steps in COVID-19 research and health policy.
Objective: To investigate the 1-year trajectory of cognitive changes in older COVID-19 survivors.
Design, Setting, And Participants: This cohort study recruited 3233 COVID-19 survivors 60 years and older who were discharged from 3 COVID-19-designated hospitals in Wuhan, China, from February 10 to April 10, 2020. Their uninfected spouses (N = 466) were recruited as a control population. Participants with preinfection cognitive impairment, a concomitant neurological disorder, or a family history of dementia were excluded, as well as those with severe cardiac, hepatic, or kidney disease or any kind of tumor. Follow-up monitoring cognitive functioning and decline took place at 6 and 12 months. A total of 1438 COVID-19 survivors and 438 control individuals were included in the final follow-up. COVID-19 was categorized as severe or nonsevere following the American Thoracic Society guidelines.
Main Outcomes And Measures: The main outcome was change in cognition 1 year after patient discharge. Cognitive changes during the first and second 6-month follow-up periods were assessed using the Informant Questionnaire on Cognitive Decline in the Elderly and the Telephone Interview of Cognitive Status-40, respectively. Based on the cognitive changes observed during the 2 periods, cognitive trajectories were classified into 4 categories: stable cognition, early-onset cognitive decline, late-onset cognitive decline, and progressive cognitive decline. Multinomial and conditional logistical regression models were used to identify factors associated with risk of cognitive decline.
Results: Among the 3233 COVID-19 survivors and 1317 uninfected spouses screened, 1438 participants who were treated for COVID-19 (691 male [48.05%] and 747 female [51.95%]; median [IQR] age, 69 [66-74] years) and 438 uninfected control individuals (222 male [50.68%] and 216 female [49.32%]; median [IQR] age, 67 [66-74] years) completed the 12-month follow-up. The incidence of cognitive impairment in survivors 12 months after discharge was 12.45%. Individuals with severe cases had lower Telephone Interview of Cognitive Status-40 scores than those with nonsevere cases and control individuals at 12 months (median [IQR]: severe, 22.50 [16.00-28.00]; nonsevere, 30.00 [26.00-33.00]; control, 31.00 [26.00-33.00]). Severe COVID-19 was associated with a higher risk of early-onset cognitive decline (odds ratio [OR], 4.87; 95% CI, 3.30-7.20), late-onset cognitive decline (OR, 7.58; 95% CI, 3.58-16.03), and progressive cognitive decline (OR, 19.00; 95% CI, 9.14-39.51), while nonsevere COVID-19 was associated with a higher risk of early-onset cognitive decline (OR, 1.71; 95% CI, 1.30-2.27) when adjusting for age, sex, education level, body mass index, and comorbidities.
Conclusions And Relevance: In this cohort study, COVID-19 survival was associated with an increase in risk of longitudinal cognitive decline, highlighting the importance of immediate measures to deal with this challenge.
Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances.
Jiang Q, Liu J, Huang S, Wang X, Chen X, Liu G Signal Transduct Target Ther. 2025; 10(1):76.
PMID: 40059211 PMC: 11891338. DOI: 10.1038/s41392-025-02145-7.
DU S, Fang L, Li Y, Liu S, Luo X, Zeng S J Zhejiang Univ Sci B. 2025; 26(2):172-184.
PMID: 40015936 PMC: 11867782. DOI: 10.1631/jzus.B2300831.
Closing the gap in dementia research by community-based cohort studies in the Chinese population.
Zhou X, Xiao Z, Wu W, Chen Y, Yuan C, Leng Y Lancet Reg Health West Pac. 2025; 55:101465.
PMID: 39902152 PMC: 11788756. DOI: 10.1016/j.lanwpc.2025.101465.
SARS-CoV-2 membrane protein induces neurodegeneration via affecting Golgi-mitochondria interaction.
Wang F, Han H, Wang C, Wang J, Peng Y, Chen Y Transl Neurodegener. 2024; 13(1):68.
PMID: 39726060 PMC: 11674522. DOI: 10.1186/s40035-024-00458-1.
von Etzdorf A, Harzen M, Heinrichs H, Seifert H, Groiss S, Balloff C Front Hum Neurosci. 2024; 18:1468204.
PMID: 39677403 PMC: 11638161. DOI: 10.3389/fnhum.2024.1468204.